Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Interest & Investment Income (2022 - 2025)

BioXcel Therapeutics has reported Interest & Investment Income over the past 4 years, most recently at $321000.0 for Q4 2025.

  • Quarterly results put Interest & Investment Income at $321000.0 for Q4 2025, down 12.77% from a year ago — trailing twelve months through Dec 2025 was $1.1 million (down 59.03% YoY), and the annual figure for FY2025 was $1.1 million, down 59.03%.
  • Interest & Investment Income for Q4 2025 was $321000.0 at BioXcel Therapeutics, up from $236000.0 in the prior quarter.
  • Over the last five years, Interest & Investment Income for BTAI hit a ceiling of $2.0 million in Q1 2023 and a floor of $15000.0 in Q1 2022.
  • Median Interest & Investment Income over the past 4 years was $643500.0 (2024), compared with a mean of $740375.0.
  • Biggest five-year swings in Interest & Investment Income: soared 13333.33% in 2023 and later tumbled 70.54% in 2025.
  • BioXcel Therapeutics' Interest & Investment Income stood at $1.5 million in 2022, then crashed by 36.34% to $946000.0 in 2023, then tumbled by 61.1% to $368000.0 in 2024, then dropped by 12.77% to $321000.0 in 2025.
  • The last three reported values for Interest & Investment Income were $321000.0 (Q4 2025), $236000.0 (Q3 2025), and $230000.0 (Q2 2025) per Business Quant data.